Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy

Am J Transplant. 2016 Aug;16(8):2496-7. doi: 10.1111/ajt.13786. Epub 2016 Apr 21.
No abstract available

Keywords: cancer/malignancy/neoplasia: chemotherapy; clinical research/practice; immunosuppression/immune modulation; kidney (allograft) function/dysfunction; kidney transplantation/nephrology; organ transplantation in general; rejection; signaling/signaling pathways.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Squamous Cell / drug therapy
  • Cyclosporine / therapeutic use
  • Graft Rejection / chemically induced
  • Graft Rejection / drug therapy
  • Graft Rejection / pathology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation
  • Lung Neoplasms / drug therapy
  • Male
  • Nivolumab
  • Prednisone / therapeutic use
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • Cyclosporine
  • Prednisone